News shortcuts: From the Courts | Top Headlines | VAT (Value Added Tax) | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | Professional Updates | Corporate Law | Markets | Students | General | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing | GST - Goods and Services Tax
Mergers and Acquisitions »
 Notification No. 05/2020-Customs (ADD) Ministry Of Finance
 Deals of the day-Mergers and acquisitions March 6, 2020
 Deals of the day-Mergers and acquisitions March 2, 2020
 Mint Investment Summit - M&A in India: Challenges and opportunities
 Record Year 2019: Fintech Deals, Mergers and Acquisitions Study
 Deals of the day-Mergers and acquisitions February 28, 2020
 Deals of the day-Mergers and acquisitions February 4, 2020
 The mergers and acquisitions perspective
 Deals of the day-Mergers and acquisitions January 6, 2020
 Mergers and Acquisitions in Vietnam – Latest Issue of Vietnam Briefing Magazine
 Deals of the day-Mergers and acquisitions December 17, 2019

Manipal Hospitals buys Fortis Healthcare: A look at major mergers and acquisitions in the pharma industry
March, 28th 2018

With Manipal Hospital Enterprise getting the go-ahead from Fortis Healthcare's Board to take over the latter's hospitals, here's a list of major mergers and acquisitions in the pharmaceuticals sector.

As Fortis Healthcare's Board has approved the de-merger of its hospitals business to Manipal Hospital Enterprises, Dr Ranjan Pai and TPG are expected to invest a whopping Rs 3,900 crore in Manipal Hospitals.

Here's a list of major mergers and acquisitions (M&As) in the pharmaceuticals sector:

Sun Pharma-Ranbaxy merger: In a USD 4 billion deal, Sun Pharma is on track to unlock synergies of USD 300 million by merging Ranbaxy by end-FY18.

Sun Pharma-Taro acquisition: In September 2010, the Mumbai-headquartered company acquired the US-based pharma firm in a USD 273 million deal. Taro has been one of Sun’s most lucrative acquisitions, with payback within 3 years and return-of-capital of 641 percent.

RELATED NEWS
Statutory auditor Deloitte raises several red flags in Fortis Q2 and Q3 earnings review
We are trying to resolve issues, not going anywhere: Singh bros
Torrent Pharma-Elder portfolio acquisition: In a USD 323 million deal, Torrent sought to expand its India portfolio and scale up sub-optimal products. The deal was a hit for Torrent with 23 percent CAGR of Elder’s brands over FY14-17.

Jubilant-Draxis acquisition: In April 2008, Jubilant acquired Draxis in a USD 255 million deal. The acquisition was turned profitable from the second year. However, the US launch of Ruby-Fill, expected in 2010 at the time of acquisition, was delayed and the product was eventually launched in 2017.

Aurobindo Pharma-Natrol acquisition: To foray into nutraceuticals in the US, the Hyderabad-headquartered firm acquired Natrol in a USD 132.5 million deal.

Aurobindo Pharma – Actavis Western Europe biz acquisition: In 2014, Aurobindo took over Actavis in a EUR 30 million deal to expand its presence and portfolio in Europe.

Home | About Us | Terms and Conditions | Contact Us
Copyright 2020 CAinINDIA All Right Reserved.
Designed and Developed by Ritz Consulting